The importance of a correct diagnosis in breast implant-associated anaplastic large cell lymphoma: Case report

Paola Iturralde-RosasPriego 1, Daniela Stuht-Lopez 1, *, Javier Gomezpedroso-Rea 1, Miguel Angel Mancera-Resendiz 1, Manuel Ubiergo-García 1, Verónica Gutiérrez-García 2, Diego López-Gutiérrez 2 and Nicole Elbjorn-Medina 2

1 Specialty Breast Group, Hospital Angeles del Pedregal.
2 Plastic Surgery, Hospital Angeles del Pedregal.
3 Facultad Mexicana de Medicina, Universidad La Salle.
 
Research Article
International Journal of Science and Technology Research Archive, 2023, 04(01), 312–317.
Article DOI: 10.53771/ijstra.2023.4.1.0048
Publication history: 
Received on 09 February 2023; revised on 18 March 2023; accepted on 20 March 2023
 
Abstract: 
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare neoplasm responsible for 0.04% to 0.5% of all cases of breast disease. It occurs in patients with a previous history of breast implants that generally progress without complications during the first years of post-operatory and is mainly associated with macro-textured implants. Due to its low incidence, it does not represent the first probable diagnosis in patients with a breast tumor. This article reports the case of a patient with BIA-ALCL initially treated as a Hodgkin's lymphoma. We emphasize the importance of a correct and complete diagnosis by immunohistochemistry before imaging in patients that develop a breast tumor associated with the prosthetic capsule after breast implant surgery and its adequate treatment, including surgery.
 
Keywords: 
BIA-LCL; Immunohistochemistry; CD30; ALK
 
Full text article in PDF: